Grand Pharmaceutical Group logo

Grand Pharmaceutical Group(SEHK) 0512

Market CapHK$16.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1996)-27%
5 Year-29%
1 Year-44%
1 Month-6%
HK$4.63
-2.22%
-0.11Today
Grand Pharmaceutical Group last closing stock price
MetricPriceDate
Last closeHKD 4.632026-10-15
Grand Pharmaceutical Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.32%HKD 4.742026-10-08
1 month-5.7%HKD 4.912026-09-15
3 month-10.27%HKD 5.162026-07-17
Year to date-41.02%HKD 7.852025-12-31
1 year-44.15%HKD 8.292025-10-15
3 year+10.77%HKD 4.182023-10-16
5 year-29.31%HKD 6.552021-10-15
Since inception-27.43%HKD 6.531996-01-05

Grand Pharmaceutical Group Financials at a Glance

Market Cap

HK$16.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

HK$24.27B

Net Income (TTM)

HK$3.21B

EPS (TTM)

HK$0.32

P/E Ratio

14.30

Dividend

HK$0.17

Beta (Volatility)

0.04 (Low)

Price

HK$4.63

Volume

3,452,500

Open

HK$4.64

Previous Close

HK$4.74

Daily Range

HK$4.62 - HK$4.74

52-Week Range

HK$4.53 - HK$8.97

Estimated Earnings Date

Mar 17, 2027

0512 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Grand Pharmaceutical Group

Grand Pharmaceutical Group Limited is a prominent investment holding company engaged in the research, development, manufacture, and sale of pharmaceutical preparations, medical devices, and healthcare products. The company operates across various sectors, including respiratory, ophthalmology, and biotechnology, with a strong presence in China and international markets.

Products and Services
  • Pharmaceutical preparations and medical devices
  • Biotechnology and healthcare products
  • Agrochemicals and Chinese medicine
Growth Outlook
  • Strategic partnerships with leading institutions enhance R&D capabilities
  • Expansion into international markets supports revenue growth
  • Focus on innovative healthcare solutions aligns with market demand
Financial Highlights
  • Recent quarterly revenue of 6.39 billion HKD, reflecting strong performance
  • TTM net income margin of 9.02%, indicating profitability
  • Dividend yield of 3.57% offers attractive returns to shareholders
Grand Pharmaceutical Group Limited has established itself as a key player in the pharmaceutical industry, leveraging its extensive product portfolio and strategic collaborations. The company's focus on innovation and expansion into new markets positions it well for future growth. Recent financial performance highlights a robust revenue stream and profitability, making it an appealing option for investors interested in the healthcare sector. The company's commitment to research and development, coupled with its diverse offerings, underscores its potential for sustained success in a competitive landscape.
AI Generated • Oct 14, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

12,614

CEO

Chao Zhou

Website

www.grandpharma.cn

Headquarters

Hong Kong, HK

0512 Financials

Key Financial Metrics (TTM)

Gross Margin

52.11%

Operating Margin

11.51%

Net Income Margin

9.02%

Return on Equity

6.61%

Return on Capital

4.80%

Return on Assets

4.03%

Earnings Yield

6.99%

Dividend Yield

3.65%

Payout Ratio

52.93%

Stock Overview

Market Cap

HK$16.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.50B

Volume

3.45M

Avg. Volume

4.76M

Financials (TTM)

Gross Profit

HK$13.30B

Operating Income

HK$2.90B

EBITDA

HK$5.17B

Operating Cash Flow

HK$3.21B

Capital Expenditure

-HK$1.30B

Free Cash Flow

HK$1.91B

Cash & ST Invst.

HK$1.27B

Total Debt

HK$5.05B

Grand Pharmaceutical Group Performance Analysis

Grand Pharmaceutical Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31HKD 9,562,285,00011.2%
20232023-12-31HKD 10,529,590,00010.1%
20242024-12-31HKD 11,644,892,00010.6%
20252025-12-31HKD 12,283,271,0005.5%
Grand Pharmaceutical Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-7.4%
Q22025-06-309.1%
Q42025-12-311.1%
Q22026-06-303.4%
Grand Pharmaceutical Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31HKD 0.59-13.3%
20232023-12-31HKD 0.54-8.7%
20242024-12-31HKD 0.7031.5%
20252025-12-31HKD 0.35-49.7%
Grand Pharmaceutical Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-40.9%
Q22025-06-3026.9%
Q42025-12-31-93.8%
Q22026-06-301363.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

HK$6.39B

+5.7%

Gross Profit

HK$3.37B

-6.2%

Gross Margin

52.71%

N/A

Market Cap

HK$16.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$1.29M

N/A

Employees

12,614

N/A

Net Income

HK$1.06B

-31.9%

EBITDA

HK$1.47B

-31.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

HK$1.27B

-46.0%

Total Debt

HK$5.05B

+11.2%

Accounts Receivable

HK$5.45B

+18.5%

Inventory

HK$1.48B

+14.4%

Long Term Debt

HK$3.37B

+62.8%

Short Term Debt

HK$1.69B

-32.4%

Return on Assets

4.03%

N/A

Return on Invested Capital

6.57%

N/A

Free Cash Flow

-HK$132.92M

-157.8%

Operating Cash Flow

HK$51.48M

-63.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
CCCCCC Intelligent Solutions
$7.62-0.33%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$102.51-7.26%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$45.57+7.16%
INTCIntel
$94.16-4.04%

Questions About 0512

What is the current price of Grand Pharmaceutical Group?

Grand Pharmaceutical Group is trading at HK$4.63 per share.

What is the 52-week range for Grand Pharmaceutical Group?

Over the past 52 weeks, Grand Pharmaceutical Group has traded between HK$4.53 and HK$8.97.

How much debt does Grand Pharmaceutical Group have?

As of the most recent reporting period, Grand Pharmaceutical Group reported total debt of HK$4.72B.

How much cash does Grand Pharmaceutical Group have on hand?

Grand Pharmaceutical Group reported HK$1.16B in cash and cash equivalents in its most recent financial results.

What is Grand Pharmaceutical Group’s dividend yield?

Grand Pharmaceutical Group currently has a dividend yield of 3.65%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services